정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 422 | Active, not recruiting | Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress | Covid19 | Biological: Ampion Other: Standard of Care |
Phase 1 | Ampio Pharmaceuticals. Inc. | INDUSTRY | 40 | All | 18 Years | Research Site, Colorado Springs, Colorado, United States |
| 421 | Recruiting | Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients | COVID-19 | Drug: Niclosamide Drug: Placebo |
Phase 3 | NeuroBo Pharmaceuticals Inc. | INDUSTRY | 436 | All | 18 Years | Helen Keller Hospital, Sheffield, Alabama, United States Baptist Health Research Institute, Jacksonville, Florida, United States AdventHealth Tampa, Tampa, Florida, United States University of Missouri Health Care, Columbia, Missouri, United States Therapeutic Concepts, PA, Houston, Texas, United States Memorial Hermann Memorial City Medical Center, Houston, Texas, United States Memorial Hermann Southeast Hospital, Houston, Texas, United States |
| 420 | Completed | Study of Open Label Losartan in COVID-19 | COVID-19 | Drug: Losartan | Phase 1 | University of Kansas Medical Center | OTHER | 34 | All | 18 Years | University of Kansas Medical Center, Kansas City, Kansas, United States |
| 419 | Recruiting | Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19 | SARS-CoV Infection | Drug: Placebo Drug: DuACT |
Phase 2 | University of Witwatersrand, South Africa, SynaVir | OTHER | 80 | All | 18 Years ~ 75 Years | Sunnyside Office Park, Johannesburg, Gauteng, South Africa |
| 418 | Completed | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | CoronaVirus Induced Disease-2019 (COVID-19) | Drug: Ibrutinib Drug: Placebo |
Phase 2 | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | INDUSTRY | 46 | All | 18 Years | Stanford Univ School Medicine /ID# 221954, Stanford, California, United States Medstar Washington Hospital Center /ID# 221886, Washington, District of Columbia, United States GW Medical Faculty Associates /ID# 222023, Washington, District of Columbia, United States Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States University of Miami /ID# 223227, Miami, Florida, United States Triple O Research Institute /ID# 222944, West Palm Beach, Florida, United States Brigham & Women's Hospital /ID# 221847, Boston, Massachusetts, United States Beth Israel Deaconess Medical Center /ID# 222994, Boston, Massachusetts, United States Intermountain Healthcare /ID# 221955, Salt Lake City, Utah, United States |
| 417 | Recruiting | Study of PBI-0451 in Healthy Subjects. | Covid19 | Drug: PBI-0451 Dose 1 Drug: PBI-0451 Dose 2 Drug: PBI-0451 Dose 3 Drug: PBI-0451 Dose 4 Drug: Ritonavir Drug: Midazolam Drug: Placebo Drug: PBI-0451 |
Phase 1 | Pardes Biosciences, Inc. | INDUSTRY | 120 | All | 18 Years ~ 59 Years | Auckland City Hospital, Auckland, New Zealand |
| 416 | Active, not recruiting | Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older | COVID-19 (Healthy Volunteers) | Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 1 Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 2 Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 1 Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 2 Biological: SARS-CoV-2 vaccine formulation 2 without adjuvant Biological: Placebo (0.9% normal saline) |
Phase 2 | Sanofi Pasteur, a Sanofi Company, GlaxoSmithKline | INDUSTRY | 440 | All | 18 Years | Investigational Site Number 8400004, Birmingham, Alabama, United States Investigational Site Number 8400012, Rolling Hills Estates, California, United States Investigational Site Number 8400011, Hollywood, Florida, United States Investigational Site Number 8400019, Melbourne, Florida, United States Investigational Site Number 8400016, Boston, Massachusetts, United States Investigational Site Number 8400002, Omaha, Nebraska, United States Investigational Site Number 8400001, Rochester, New York, United States Investigational Site Number 8400007, Rochester, New York, United States Investigational Site Number 8400008, Cleveland, Ohio, United States Investigational Site Number 8400003, Philadelphia, Pennsylvania, United States Investigational Site Number 8400014, Mount Pleasant, South Carolina, United States |